Colon cancer-induced interleukin-35 inhibits beta-catenin-mediated pro-oncogenic activity

Yueqiang Jiang; Yanling Ma; RuiChao Li; JianHai Sun

doi:10.18632/oncotarget.22857

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

This article has been retracted. Retraction in: Oncotarget. 2022; 13:1322-1322.

Colon cancer-induced interleukin-35 inhibits beta-catenin-mediated pro-oncogenic activity

Yueqiang Jiang, Yanling Ma, RuiChao Li _ and JianHai Sun

PDF | HTML | How to cite

Oncotarget. 2018; 9:11989-11998. https://doi.org/10.18632/oncotarget.22857

Metrics: PDF 2130 views | HTML 3047 views | ?

Abstract

Yueqiang Jiang1,*, Yanling Ma2,*, RuiChao Li1 and JianHai Sun2

1Department of Gerontology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei Province, China

2Department of Oncology, the Third People’s Hospital, Wuhan, Hubei Province, China

*Co-first author

Correspondence to:

RuiChao Li, email: [email protected]

JianHai Sun, email: [email protected]

Keywords: colon cancer; IL-35; β-catenin; inhibition; metastasis

Received: May 23, 2017 Accepted: November 11, 2017 Published: December 01, 2017

ABSTRACT

The occurrence and development of colon cancer is closely related to inflammation. Therefore, this study was conducted a current retrospective research to study the effect of IL-35 (interleukin 35), a newly identified anti-infective factor, on colon cancer development. The expression of IL-35 in colon cancer samples and their adjacent normal mucosa by real-time PCR, ELISA (enzyme-linked immunosorbent assay). The effect of IL-35 on patient survival, colon cancer progression, and its effect on Wnt/β-catenine signaling pathway was also assessed. IL-35 is minimally expressed in colon cancer tissues but is highly expressed in adjacent normal tissues. The down-regulation of IL-35 was significantly associated with the American Cancer Joint Committee stage and overall survival of colon cancer patients. The overexpression of IL-35 in colon cancer cells inhibits cell migration, invasion, proliferation, colony formation and cancer stem cells by inhibiting beta-catenin. IL-35 inhibits colon neoplasms in mouse. Our results suggest that IL-35 has an inhibitory effect on the development of colon cancer as a novel prognostic indicator and potential therapeutic target.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 22857

Publication Alerts

Oncoscience

Post-Publication Promotion

Research Papers:

Colon cancer-induced interleukin-35 inhibits beta-catenin-mediated pro-oncogenic activity

Abstract